SOURCE: DiamiR Biosciences Corp.

DiamiR Biosciences Corp.

March 18, 2016 08:02 ET

DiamiR Announces Oral Presentation at Biomarkers Summit 2016

MONMOUTH JUNCTION, NJ--(Marketwired - March 18, 2016) -  DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today that the company's Chief Scientific Officer, Dr. Samuil Umansky, will present at the Biomarkers Summit, 5th Neurological Biomarkers Conference taking place in San Diego, CA, March 21-23.

Session: CSF & Blood Based Biomarker Approaches

Title: Circulating brain-enriched microRNAs as biomarkers for early detection and differential diagnosis of neurodegenerative diseases

Date/Time: Tuesday, March 22, 2016, 12:15 pm PT

Location: The Westin San Diego

About DiamiR

DiamiR is a privately held molecular diagnostics company focused on developing targeted, minimally invasive tests for early detection, differential diagnosis and monitoring of Mild Cognitive Impairment, Alzheimer's and Parkinson's diseases, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and is being developed for screening, patient stratification as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic and clinical centers and disease foundations. For more information, please visit the company's website at www.diamirbio.com

Please Note : This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.

Contact Information